Reason for request
Inclusion on list of products reimbursed by National Insurance and for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of FIRMAGON is substantial.
|
Clinical Added Value
| no clinical added value |
In the context of the current strategy for treatment of advanced prostate cancer, with a combination of a Gn-RH analogue and an antiandrogen in the first month of treatment, FIRMAGON provides no improvement in actual benefit (IAB level V).
|
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
7EbXbRmAypHsagTR